1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mercury Laboratories Ltd.

Mercury Laboratories Ltd.

BBSE:MERCURYLAB
731.05
INR
+1.05
(+0.14%)
34.69EPS
22.68P/E
944.04MMarket Cap
Mercury Laboratories Ltd.
BSE:MERCURYLAB
(Bombay Stock Exchange)

Recent

price

731.05

P/E

ratio

22.68

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
345.41
343.26
395.98
400.23
432.23
462.67
477.24
571.68
482.7
627.78
629.66
625.84
632.81
614.48
Revenue per Share
26.85
27.61
32.69
22.53
16.78
23.63
26.9
44.48
29.68
46.49
47.12
26.21
40.28
34.69
Basic EPS, GAAP
8.14
16.19
-3.13
3.51
10.43
1.94
36.26
29.95
27.29
11.63
16.28
-34.85
8.96
- -
Free Cash Flow per Basic Share
1.74
1.74
1.81
1.81
1.81
1.81
1.81
3.5
2
3.5
3.5
3.5
3.5
- -
Dividend per Share
128.38
151.18
182.06
203.94
219.56
241.38
266.48
307.46
335.89
380.24
423.65
446.41
483.97
- -
Book Value per Share
128.38
151.18
181.73
202.61
218.89
240.78
266.11
306.76
335.42
379.9
423.44
446.19
483.92
- -
Tangible Book Value per Share
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Basic Weighted Avg Shares
414
412
475
480
519
555
573
686
579
753
756
751
759
738
Sales/Revenue/Turnover
13.77
13.39
11.13
11.99
5.67
7.38
7.79
13.44
8.25
8.76
10.14
9.87
7.4
6.2
Operating Margin (%)
9
12
12
13
15
16
19
19
25
25
28
29
34
33
Depreciation Expense
32
33
39
27
20
28
32
53
36
56
57
31
48
42
Net Income, GAAP
32.79
28.05
20.53
44.77
18.02
29.98
25.43
32.51
29.25
25.06
18.3
32.54
27.17
24.04
Effective Tax Rate (%)
7.77
8.04
8.26
5.63
3.88
5.11
5.64
7.78
6.15
7.41
7.48
4.19
6.37
5.64
Profit Margin (%)
13
22
111
150
167
150
164
190
195
253
272
241
333
- -
Working Capital
39
19
66
74
97
85
63
62
29
25
29
38
70
- -
LT Debt
154
181
218
245
263
290
320
369
403
456
508
536
581
- -
Total Equity
- -
14.03
12.57
8.15
6.51
7.47
7.93
11.99
7.07
9.33
9.85
5.1
6.26
- -
Return on Invested Capital (%)
- -
16.46
18.12
9.66
7.06
8.89
9.05
13.25
8.16
11.5
10.58
5.7
7.9
- -
Return on Capital (%)
- -
19.75
19.62
11.67
7.92
10.26
10.59
15.5
9.23
12.98
11.72
6.02
8.66
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
14
- -
LT Borrowings
- -
67
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
973
840
944

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
449
- -
Cash, Cash Equivalents & STI
- -
55
- -
Accounts Receivable, Net
- -
258
- -
Inventories
- -
71
- -
Total Current Liabilities
- -
117
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
14
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.31%
9.53%
8.41%
Free Cash Flow
119.25%
-93.22%
-125.7%
Net Income, GAAP
9.74%
6.81%
53.71%
Sales/Revenue/Turnover
5.43%
3.06%
1.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
167
182
196
207
751
2026
181
190
184
204
759
2027
160
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.85
4.17
9.94
9.25
26.21
2026
8.06
13.69
8.31
10.21
40.28
2027
2.48
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3.5
2026
- -
- -
- -
- -
3.5
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mercury Laboratories Limited (MERCURYLAB.BO), founded in 1962 and headquartered in Vadodara, Gujarat, India, manufactures, markets, exports and distributes pharmaceutical formulations primarily focused on mother and child healthcare, gynecology and pediatrics segments; its core products encompass tablets, oral liquids, small volume parenterals, ophthalmic and ear drops across therapy areas including analgesics, anti-inflammatories, anti-pyretics, anthelmintics, antibiotics, anti-coagulants, anti-platelets, haemostats, anti-fungals, anti-hypertensives, anti-malarials, cardiovascular, central nervous system, gastro-intestinal, hypoglycemics, multivitamins, protein supplements, respiratory, anti-allergics, steroids, urinary tract and uterine stimulants; the company operates state-of-the-art facilities spanning 435,600 square feet with separate units for tablets, liquids, injectables and ophthalmics, holding international accreditations such as WHO-GMP, NAFDAC Nigeria, FDA Ghana, DPML Ivory Coast, MoH Congo, CDDA Sri Lanka and MoH Cambodia, serving domestic and global markets in Africa, Asia and beyond. In recent developments, Mercury Laboratories reported standalone net profit surging 228% to Rs 1.64 crore for the quarter ended September 2025, with sales up 4.51% year-over-year to Rs 19.01 crore, alongside March 2025 net sales growth of 18.95% to Rs 20.66 crore, reflecting improved operational performance amid stable promoter holding of 73.66% and minimal debt.